{"downloaded": true, "htmlmade": false, "full": {"id": "29695516", "source": "MED", "pmid": "29695516", "pmcid": "PMC6107856", "fullTextIdList": {"fullTextId": "PMC6107856"}, "doi": "10.1182/blood-2017-10-812701", "title": "Phase 1 study of the PI3K\u03b4 inhibitor INCB040093 \u00b1 JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.", "authorString": "Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM.", "authorList": {"author": [{"fullName": "Phillips TJ", "firstName": "Tycel J", "lastName": "Phillips", "initials": "TJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI."}}}, {"fullName": "Forero-Torres A", "firstName": "Andres", "lastName": "Forero-Torres", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL."}}}, {"fullName": "Sher T", "firstName": "Taimur", "lastName": "Sher", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Mayo Clinic, Jacksonville, FL."}}}, {"fullName": "Diefenbach CS", "firstName": "Catherine S", "lastName": "Diefenbach", "initials": "CS", "authorId": {"@type": "ORCID", "#text": "0000-0003-1116-3246"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Perlmutter Cancer Center, New York University School of Medicine, New York, NY."}}}, {"fullName": "Johnston P", "firstName": "Patrick", "lastName": "Johnston", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Mayo Clinic, Rochester, MN."}}}, {"fullName": "Talpaz M", "firstName": "Moshe", "lastName": "Talpaz", "initials": "M", "authorId": {"@type": "ORCID", "#text": "0000-0003-3361-3981"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI."}}}, {"fullName": "Pulini J", "firstName": "Jennifer", "lastName": "Pulini", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Incyte Corporation, Wilmington, DE."}}}, {"fullName": "Zhou L", "firstName": "Li", "lastName": "Zhou", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Incyte Corporation, Wilmington, DE."}}}, {"fullName": "Scherle P", "firstName": "Peggy", "lastName": "Scherle", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Incyte Corporation, Wilmington, DE."}}}, {"fullName": "Chen X", "firstName": "Xuejun", "lastName": "Chen", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Incyte Corporation, Wilmington, DE."}}}, {"fullName": "Barr PM", "firstName": "Paul M", "lastName": "Barr", "initials": "PM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Wilmot Cancer Institute, University of Rochester, Rochester, NY."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0003-1116-3246"}, {"@type": "ORCID", "#text": "0000-0003-3361-3981"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "3", "volume": "132", "journalIssueId": "2708520", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "Blood", "ISOAbbreviation": "Blood", "medlineAbbreviation": "Blood", "NLMid": "7603509", "ISSN": "0006-4971", "ESSN": "1528-0020"}}, "pubYear": "2018", "pageInfo": "293-306", "abstractText": "Because both phosphatidylinositol 3-kinase \u03b4 (PI3K\u03b4) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3K\u03b4 inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas. Final results are reported. Overall, 114 patients were treated (monotherapy, n = 49; combination therapy, n = 72 [7 patients crossed over from monotherapy to combination]). INCB040093 100 mg twice daily (monotherapy) and INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination) were the recommended phase 2 doses. One dose-limiting toxicity (gastrointestinal bleed secondary to gastric diffuse large B-cell lymphoma [DLBCL] regression) occurred with monotherapy. The most common serious adverse events with monotherapy were pneumonia (n = 5) and pyrexia (n = 4), and with combination <i>Pneumocystis jiroveci</i> pneumonia (n = 5), pneumonia (unrelated to <i>P jiroveci</i>; n = 5), and pyrexia (n = 4). Grade 3 or higher transaminase elevations were less common with combination. INCB040093 was active across the B-cell lymphomas; 63% of patients (5/8) with follicular lymphoma responded to monotherapy. Adding itacitinib provided promising activity in select subtypes, with responses of 67% (14/21) in classic Hodgkin lymphoma (vs 29% [5/17] with monotherapy) and 31% (4/13) in nongerminal center B-cell-like DLBCL. INCB040093 with/without itacitinib was tolerated and active in this study, and is a promising treatment strategy for patients with select R/R B-cell lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT01905813.", "affiliation": "Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, B-Cell", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DG", "qualifierName": "diagnostic imaging", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Protein Kinase Inhibitors", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Combined Modality Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Research Design"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Janus Kinase 1", "meshQualifierList": {"meshQualifier": {"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Class I Phosphatidylinositol 3-Kinases", "meshQualifierList": {"meshQualifier": {"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}}}]}, "chemicalList": {"chemical": [{"name": "Protein Kinase Inhibitors", "registryNumber": "0"}, {"name": "PIK3CD protein, human", "registryNumber": "EC 2.7.1.137"}, {"name": "Class I Phosphatidylinositol 3-Kinases", "registryNumber": "EC 2.7.1.137"}, {"name": "Janus Kinase 1", "registryNumber": "EC 2.7.10.2"}, {"name": "JAK1 protein, human", "registryNumber": "EC 2.7.10.2"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2017-10-812701"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6107856"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2017-10-812701"}]}, "commentCorrectionList": {"commentCorrection": {"id": "30026300", "source": "MED", "reference": "Blood. 2018 Jul 19;132(3):240-241", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "12", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-07-09", "dateOfCreation": "2018-04-27", "firstIndexDate": "2018-04-27", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2021-02-02", "electronicPublicationDate": "2018-04-25", "firstPublicationDate": "2018-04-25"}, "abstract": "Because both phosphatidylinositol 3-kinase \u03b4 (PI3K\u03b4) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3K\u03b4 inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas. Final results are reported. Overall, 114 patients were treated (monotherapy, n = 49; combination therapy, n = 72 [7 patients crossed over from monotherapy to combination]). INCB040093 100 mg twice daily (monotherapy) and INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination) were the recommended phase 2 doses. One dose-limiting toxicity (gastrointestinal bleed secondary to gastric diffuse large B-cell lymphoma [DLBCL] regression) occurred with monotherapy. The most common serious adverse events with monotherapy were pneumonia (n = 5) and pyrexia (n = 4), and with combination <i>Pneumocystis jiroveci</i> pneumonia (n = 5), pneumonia (unrelated to <i>P jiroveci</i>; n = 5), and pyrexia (n = 4). Grade 3 or higher transaminase elevations were less common with combination. INCB040093 was active across the B-cell lymphomas; 63% of patients (5/8) with follicular lymphoma responded to monotherapy. Adding itacitinib provided promising activity in select subtypes, with responses of 67% (14/21) in classic Hodgkin lymphoma (vs 29% [5/17] with monotherapy) and 31% (4/13) in nongerminal center B-cell-like DLBCL. INCB040093 with/without itacitinib was tolerated and active in this study, and is a promising treatment strategy for patients with select R/R B-cell lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT01905813.", "journaltitle": "Blood", "authorinfo": ["Phillips TJ", "Forero-Torres A", "Sher T", "Diefenbach CS", "Johnston P", "Talpaz M", "Pulini J", "Zhou L", "Scherle P", "Chen X", "Barr PM"], "title": "Phase 1 study of the PI3K\u03b4 inhibitor INCB040093 \u00b1 JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma."}